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Abstract Lung cancer is the most common cancer world-
wide. Up to 85% of lung cancer cases are diagnosed as non-
small cell lung cancer (NSCLC). The effectiveness of NSCLC
treatment is expected to be improved through the implemen-
tation of robust and specific biomarkers. MicroRNAs
(miRNAs) are small, non-coding molecules that play a key
role in the regulation of basic cellular processes, including
differentiation, proliferation and apoptosis, by controlling
gene expression at the post-transcriptional level.
Deregulation of miRNA activity results in the loss of homeo-
stasis and the development of a number of pathologies, includ-
ing lung cancer. During lung carcinogenesis, miRNAs exhibit
dual regulatory function: they act as oncogenes to promote
cancer development or as tumour suppressors. Unique
miRNA sequences have been detected in malignant tissues
and corresponding healthy tissues. Furthermore, stable forms
of tumour-related miRNAs are detectable in the peripheral
blood of patients with NSCLC. The potential benefits of using
extracellular miRNAs present in body fluids as part of the
diagnostic evaluation of cancer include low invasiveness
(compared with tumour cell/tissue sampling), and the repeat-
ability and ease of obtaining the specimens. Apart from the
diagnostic applications of altered miRNA expression profiles,
the dual regulatory role of miRNA in cancer might drive the
further development of personalised therapies in NSCLC. The
clinical usefulness of miRNA expression analysis to predict
the efficacy of various treatment strategies including surgery,
radio- and chemotherapy, and targeted therapies has been
evaluated in NSCLC. Also, the capacity of a single miRNA
to regulate the expression of multiple genes simultaneously
presents an opportunity to use these small molecules in
personalised therapy as individualised therapeutic tools.
Key Points
miRNAs could serve as prognostic biomarkers in
NSCLC. 
miRNA expression analysis is currently assessed to
predict the efficacy of various treatment strategies 
including surgery, radio-   and chemotherapy, and 
targeted therapies. 
The capacity of a single miRNA to regulate the 
expression of multiple genes could be used in 
personalised therapy.
1 Introduction
Lung cancer is the most common cancer worldwide and causes
over 1.6 million deaths per year [1]. Up to 85% of lung cancer
cases are diagnosed as non-small cell lung cancer (NSCLC).
High mortality of NSCLC results from the fact that a majority
of patients are diagnosed with advanced disease, when the pos-
sibility of offering potentially curative surgical treatment is lim-
ited. Five-year survival rates are greatly improved when the
disease is found while still localized; unfortunately, only 16%
of lung cancers are diagnosed at this early stage. For advanced
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stages with metastatic tumours the 5-year survival rate is only
4% [2]. Key problems are the lack of effective tools and
methods for early detection of NSCLC and its resistance to
the majority of the currently used therapies.
The past two decades have seen considerable progress in
research on the underlying molecular mechanisms of lung
carcinogenesis and the recognition of NSCLC as a disease
with complex genetics. This gave hope for realistic chances
to successfully implement the concept of personalised medi-
cine in the management of lung cancer. The personalisation of
diagnostic and therapeutic approaches implies the correct sub-
classification of a tumour type based on unique histological
and molecular features determining the choice of treatment.
The final objective of a personalised approach is to improve a
disappointing overall survival in NSCLC.
One prerequisite for the development of personalised med-
icine is the identification of robust biomarkers to guide clinical
decision-making [3, 4]. In this context, the potential of small,
non-coding microRNA (miRNA) molecules has rapidly be-
come apparent. The clinical applicability of miRNAs in the
diagnosis and treatment of NSCLC is currently under evalua-
tion (Fig. 1). Although no miRNA biomarker has been vali-
dated and approved for cancer diagnostics to date, there are
numerous in vitro and in vivo studies that demonstrate great
clinical potential of these molecules.
The need for a personalised approach in the management of
screen-detected nodules has been recently emphasized by the
National Lung Screening Trial (NLST), the first study to show
a statistically significant 20% reduction in lung cancer mortality
among high-risk individuals screened with low-dose computed
tomography (LDCT) scans, when compared to chest X-ray [5].
However, a high rate of false positive results associated with
LDCTscreening opened a debate over the cost-effectiveness of
LDCT screening programs and the potential harms related to
overdiagnosis and radiation-induced cancers. In view of
personalised medicine, the potential role for specific, miRNA-
based biomarkers to complement the radiological modalities
and increase the total sensitivity and specificity of the lung
cancer screening process is currently being investigated [6, 7].
The last decade identified a number of genetic alterations in
NSCLC as useful predictive biomarkers and assigned a per-
manent position to molecular biology, together with histology
and radiology, in the selection of optimal treatment strategies
for lung cancer patients. In the era of ‘theranostics’, therapeu-
tics and diagnostics have been meaningfully combined to
achieve personalised pharmacotherapy. For NSCLC, much
of the work in recent years has focussed on mutations of the
epidermal growth factor receptor (EGFR) and on the abnormal
fusions of the anaplastic lymphoma kinase (ALK) or the c-ros
oncogene 1 (ROS1) genes. While conventional chemotherapy
remains a gold standard in the management of advanced
NSCLC patients without druggable genetic abnormalities, pa-
tients whose tumours harbouring specific alterations in EGFR
or ALK/ROS1 genes are adequate for the targeted therapy,
offering a prolonged progression-free survival as compared
to chemotherapy [8]. However, the relatively rapid acquisition
of resistance to such treatments that is observed in virtually all
patients significantly limits their utility and remains a substan-
tial challenge to the clinical management of advanced lung
cancers and the further development of targeted therapies.
Since molecular mechanisms of resistance have been identi-
fied, new strategies to overcome or prevent the development
of resistance have emerged, including the regulation of spe-
cific signalling pathways by epigenetic mechanisms [9].
Finally, advances in the understanding of immune evasion
strategies used by tumours enabled the development of new
immunotherapies and culminated in positive results with
checkpoint inhibitors in randomized clinical trials. Several
programmed death-1 (PD-1) and programmed death ligand-1
(PD-L1) inhibitors have been approved by the Food and Drug
Administration (FDA) to treat metastatic NSCLC. Still, many
questions remain to be addressed on immunotherapy, regard-
ing the optimal schedule of treatment, identifying proper pre-
dictive biomarkers and co-targeting of the other key modula-
tors of tumour immune response [10]. Recently, various
miRNAs have been found to target key cancer-related im-
mune pathways, which seem involved in the secretion of im-
munosuppressive or immunostimulating factors by cancer or
immune cells [11].
The pronounced role that miRNAs have across human dis-
eases, including all cancer types, led to the development of
new therapeutic strategies through identification and valida-
tion of miRNAs that are causally involved in the disease pro-
cess and the effective regulation of target-miRNA function by
a drug. Recently, the clinical trial on BMiravirsen^ (SPC3649),
a synthetic oligonucleotide complementary to miR-122 which
can sequester and inhibit the activity of this miRNA, has been
extended to long-term phase 2 study for patients with chronic
hepatitis C virus genotype 1 infection [12]. This shows some
promise for the successful implementation of currently devel-
oped miRNA-based therapeutics for malignant diseases,
which currently are still mostly evaluated in early preclinical
phases. The aim of this review is to highlight the most prom-
ising studies reported to date that investigate the clinical ap-
plicability of miRNAs, either as a biomarker or therapeutics,
in lung cancer treatment.
2 miRNA Biogenesis and Function
miRNAs are a class of non-coding, endogenous, single-
stranded small RNA molecules composed of 19–22 nucleo-
tides. miRNAs function as regulators of gene expression in
both plant and animal cells [13, 14]. It is believed that in mam-
mals including humans, miRNAs may regulate more than 50%
of all protein-encoding genes [15]. Ever since their discovery,
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the number of newly identified human miRNAs has been in-
creasing constantly, and more than 2500 known sequences
have been identified thus far [16]. This corresponds to approx-
imately 1–4% of all expressed genes in humans, and thus,
miRNAs are currently considered as one of the largest classes
of gene regulators [17–19]. miRNA molecules can regulate
genes at the post-transcriptional level by specifically
recognising and affecting messenger RNA (mRNA), depend-
ing on the degree of homology with the targeted sequence [20].
The standard miRNA biogenesis pathway consists of two
cleavage events, one nuclear and one cytoplasmic [21]. After
the cleavage, primary miRNAs are processed into active ma-
ture miRNAs through a series of biochemical steps, and
miRNA expression can be regulated at each step of biogenesis
pathway (Fig. 2).
Genes encoding miRNAs are often clustered and are not
only present in exons but also in introns and untranslated re-
gions (UTRs) [36, 37]. This configuration of transcription units
allows for simultaneous formation of both miRNA and mRNA
transcripts. The organisation of the genes encoding miRNAs
allows for the activity of polymerases II and III which are both
involved in transcribing genes encoding small RNAs [38, 39].
However, regions encoding pre-miRNA sequences have been
shown to contain approximately 2000 single nucleotide poly-
morphisms (SNPs) which may affect miRNA–mRNA interac-
tions [40]. Genetic alterations inmiRNA sequences are likely to
affect their regulatory activity and, consequently, a number of
cellular processes including carcinogenesis [41]. The
rs11614913 (C→T) SNP in pre-miR-192a2 has been linked
to a higher risk of NSCLC [42–44].
Interestingly, Czubak et al. [45] showed several miRNA
genes (miR-30d, miR-21, miR-17 and miR-155), as well as
two miRNA biogenesis genes, DICER1 and DROSHA, to be
frequently amplified in tumour tissue specimens from 254
NSCLC patients. Moreover, the copy number variation of
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Fig. 1 Potential clinical applications of miRNAs as biomarkers for
diagnosis and treatment of NSCLC. The expression of biomarker
miRNA, which may consist of a single or multiple miRNA species,
might be effectively evaluated in either tumour tissue obtained by
biopsy or blood specimens (plasma, serum) collected in a minimally
invasive manner as a so-called liquid biopsy before, during and after
the treatment. Validated miRNA signatures of lung cancer subtypes could
serve as an auxiliary tool in the diagnostic classification of the disease.
Circulating miRNA biomarkers detectable in plasma/serummight greatly
aid in the differential diagnosis of malignant and benign lung nodules
through preselecting the patients for further more expensive or invasive
procedures. The serial blood collection during the treatment also offers a
unique opportunity for therapy effectiveness monitoring in real time by
tracing the dynamic changes in expression levels of selected miRNA
biomarkers
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and the survival of NSCLC patients. Upregulation of the ex-
pression of DROSHA and DICER1 decreases or increases the
survival, respectively. This study demonstrated that gene copy
number variation may be an important mechanism of
upregulation/downregulation of miRNAs in lung cancer and
suggest an oncogenic role for DROSHA.
Abnormal regulation of miRNA expression has been
shown to interfere with important cellular processes, such as
differentiation, proliferation and apoptosis, resulting in the
loss of homoeostasis and the development of a number of
diseases including tumours [46]. Some miRNAs can act as
oncosuppressors, while others act as oncogenes that stimulate
the growth of tumours [47]. miRNAs that are overexpressed in
malignant cells (oncomiRs), such as miR-21, act as oncogenes
that promote the development of tumours by negatively regu-
lating tumour suppressor genes and/or genes that control cel-
lular processes such as differentiation and apoptosis. miRNAs
that are downregulated in cancer, such as let-7, function as
oncosuppressors and can suppress tumour development by
regulating oncogenes and/or genes involved in the cell cycle.
The various miRNA expression patterns are unique for spe-
cific tissue types. These molecules are either over- or
underexpressed depending on the tumour type [36, 48].
2.1 Extracellular miRNA
Studies conducted by several research groups have confirmed
the presence of miRNAs in various body fluids in humans,
including serum [49–51], plasma [49, 50], saliva [52], urine
[53], milk [54], cerebrospinal fluid [55] and seminal fluid
[56]. In cancer, there is a distinct relationship between the type
of biological material and the original location of the neo-
plasm (e.g. urine – bladder cancer, cerebrospinal fluid – brain
tumour etc.) which may be potentially significant to the de-
velopment of a new class of non-invasive diagnostic tests
based on extracellular nucleic acids. Accordingly, tumour-



















Fig. 2 Biogenesis of miRNA. miRNAs are transcribed by RNA
polymerase II into primary miRNAs (pri-miRNAs), which are several-
fold larger than mature miRNAs (usually 100–1000 nucleotides). In the
nucleus, pri-miRNAs are processed into precursor miRNAs (pre-
miRNAs) consisting of approximately 60–120 nucleotides by a ribonu-
clease (RNase) III displaying endonuclease activity (the Drosha RNase)
and the protein DGCR8 (Pasha). Subsequently, pre-miRNAs are folded
into the characteristic hairpin structure and transported by RAN-GTP-
dependent exportin 5 to the cytoplasm, where they are further processed
by the Dicer RNase III, to target miRNA sequences of 19–22 nucleotides.
Mature miRNA initially has the form of an asymmetric duplex of two
strands of miRNA:miRNA*. Usually, the strand that contains the less
thermostable 5′-terminus is packaged into a protein complex (RISC)
whose main component is an AGO protein. The miRISC complex can
then act in the cell or be secreted into the extracellular space inside extra-
cellular vesicles (EVs) or as complexes with RNA-binding AGO proteins
or high-density lipoproteins. There are two ways for EVs to be secreted
from donor cells: (1) microvesicles are directly shed from the cell mem-
brane; and (2) the intraluminal endosomal vesicles are released from the
multivesicular body (MVB) into the extracellular space to become
exosomes [22–35].
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related miRNAs have been found in bronchoalveolar lavage
fluid [57, 58], pleural effusion fluid [59, 60] and blood
plasma/serum [15, 51, 61] from lung cancer patients.
The mechanisms of how miRNAs can be released from cells
include both cell death (necrosis and apoptosis) and active secre-
tion [62]. In the latter, miRNAs are secreted inside exosomes and
other extracellular vesicles (EVs) or as complexes with RNA-
binding AGO proteins or high-density lipoproteins (Fig. 2).
Studies investigating miRNAs in the blood have confirmed their
high stability in both plasma and serum [51]. Biochemical anal-
yses have shown that extracellular miRNAs present in the blood
are resistant to RNases and are exceptionally stable at extreme
pH values and temperatures [49, 50]. This resistance is suggested
to be the result of miRNA selective packaging (e.g. within
exosomes or EV) and association with RNA binding proteins
such as AGO, nucleophosmin (NPM1) or ribosomal proteins
which provide a robust protective effect on miRNAs from
RNases activity [63]. Nevertheless, it is not entirely clear how
miRNAs manage their stability.
In a study by Weber et al. [64], the total amount of RNA
isolated from various body fluids was found to range widely from
113 to 48,240 μg/L. Plasma, cerebrospinal fluid, pleural effusion
fluid and urine contained less RNA than seminal fluid, saliva and
bronchoalveolar lavage fluid did. The numbers of variousmiRNA
sequences detected by real-time reverse transcription polymerase
chain reaction (RT-qPCR) ranged from204 in urine to up to 458 in
saliva. The absolute total amount of extracellular RNA in plasma
was estimated to be in the low nanomolar range. The concentra-
tion of extracellular miRNA in the plasma of healthy donors was
estimated to be approximately 100 fM [64, 65]. The concentra-
tions of individual miRNAs are therefore thought to be a fraction
of this value. Significantly increased or decreased release of certain
miRNAs into the circulation is a characteristic of individual tu-
mour types including lung cancer [66].
EV-derived miRNAs function in cell-cell communication
and play roles in various biological processes including im-
mune system regulation, inflammation and tumour develop-
ment [67]. Exosomes can be secreted bymost types of cancers
including lung cancer. One notable feature of cancer cells is
that they produce exosomes in greater amounts than normal
cells do, and this feature can be a useful diagnostic biomarker
[68]. Rabinowits et al. [67] evaluated circulating exosomal
miRNA levels of patients with lung adenocarcinoma and com-
pared them with those of patients without lung cancer, show-
ing that the miRNA signatures of exosomes paralleled those
of the miRNA expression profiles of the originating tumour
cells. Exosomes from tumours (tumour-derived exosomes)
have protumorigenic functions and can promote cancer stim-
ulatory activities such as proliferation, extracellular matrix
remodelling, migration, invasion, angiogenesis and contribute
in the metastatic cascade [69]. It is postulated that EV-derived
miRNAs are therefore potentially better disease biomarkers
than other forms of circulating miRNAs.
miRNA levels and profiles in bodily fluids may reflect not
only the body’s physiological status but, more importantly,
various pathological conditions [70]. Changes in the expres-
sion profiles of a few or multiple extracellular miRNAs may
be a useful diagnostic markers for the early detection and
identification of the tumour type and a prognostic and/or pre-
dictive marker for establishing prognosis and treatment [62].
The potential benefits of using extracellular miRNAs present
in bodily fluids, sampled via so-called liquid biopsies, as a part
of the diagnostic evaluation of cancer include low invasive-
ness compared with tumour cell/tissue sampling, repeatability
and ease of obtaining specimens. In addition, analysis of
plasma/serum as a reservoir of miRNAs released by tumour
cells from different parts of the primary tumour or from vari-
ous locations in the body (distant metastases) evades the is-
sues encountered with cellular and molecular tumour hetero-
geneity [71]. A single tumour tissue sample obtained by biop-
sy is not fully representative of the molecular changes occur-
ring in developing lung cancers, nor does it reflect the diver-
sity of tumour clones found in distant metastases. In this case,
analysis of extracellular miRNAs should not only enable dis-
ease monitoring but also allow for effective treatment moni-
toring, which seems to be a key factor in improving prognosis
[72]. Extracellular miRNA sequences might also be an early
marker of recurrence after radical treatment.
2.2 Methods of miRNA Expression Analysis
A reliable expression analysis of miRNAs, particularly extra-
cellular miRNAs, in bodily fluids still remains an analytical
challenge because of the unique characteristics of miRNA
molecules (small size, high homology among miRNAs within
the same family and low concentrations in body fluids), the
lack of standardized methodologies, and the different detec-
tion methods and sensitivities of the various commercial re-
agent kits and systems [73–75]. Currently, the methods most
commonly used for the analysis of miRNA expression include
RT-qPCR, microarrays and next-generation sequencing
(NGS). Table 1 summarises the key advantages and potential
limitations of each of these methods. In terms of equipment,
reagents and labour costs, RT-qPCR seems to be the most
suitable technique for clinical diagnostics. This method is
much cheaper than NGS and does not require extensive tech-
nical facilities and specialised bioinformatics staff to analyse
the results. While NGS is commonly regarded as the future of
molecular biology and genomics, it is undoubtedly also the
future of clinical diagnostics, as it allows simultaneous analy-
sis of a large number of DNA/RNA sequences in multiple
samples. However, the multiple advantages PCR offers make
it the current gold standard for molecular tumour diagnostics.
The low repeatability of testing in terms of selecting the
optimal panel of miRNAs as NSCLC biomarkers results from
a lack of standard methodologies and frequent errors during
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the planning stage of experiments (e.g. incorrect selection or
poor representativeness of the patient groups, incorrect pro-
cessing and storage of the specimens and insufficient statisti-
cal power of the study). There is also no consensus on the
normalisation method used for the resulting data, which is
why all steps of an analytical procedure must be validated
and standardised before any miRNA-based diagnostic method
can be implemented into clinical practice [76].
3 miRNA as Potential Biomarkers in NSCLC
miRNA expression profiles are highly specific to individual
types of cells, tissues and organs [48]. UniquemiRNA sequences
are detected in corresponding healthy and malignant tissues [77].
More than 50% of all miRNAs in humans are located in sensitive
regions of chromosomes that undergo amplification, deletion and
translocation during carcinogenesis [78, 79]. Attempts to deter-
mine the order of the epigenetic and genetic changes that occur
during lung carcinogenesis have shown that the earliest alter-
ations, which take place during the hyperplastic and metaplastic
stages, include loss of heterozygosity on chromosomes 3p and 9p
and microsatellite instability and deregulation of telomerase ex-
pression; all of these changes are progressive. In dysplastic le-
sions, chromosomal aberrations (aneuploidy), chromosomal de-
letions, methylation, mutations in suppressor genes (e.g. TP53,
FHIT, RB1, MYC) and telomerase activation are also observed.
At the pre-invasive carcinoma stage (carcinoma in situ), muta-
tions in important oncogenes (e.g. KRAS and HER2/neu) are
detected. Invasive lung carcinoma is characterised by the
presence of many various genetic and epigenetic alterations in
tumour cells [80]. This leads to deregulated expression of certain
miRNAs [81], resulting in significant changes in their concentra-
tions and compositions and, consequently, their activities (de-
scribed as miRNA under- or overexpression), and these
miRNAs are potential biomarkers of clinical relevance [82, 83].
Previous studies have confirmed the usefulness of miRNAs as
biomarkers of NSCLC [48, 84–86].
Two meta-analyses by He et al. [87] (510 patients and 465
healthy volunteers) and byWang et al. [88] (2121 patients and
1582 volunteers) provided an insight into the overall diagnos-
tic performance of miRNA and explored the influential factors
that may affect the diagnostic accuracy of miRNA in NSCLC.
In both analyses, panels composed of several miRNAs offered
a much higher diagnostic value than single miRNAs and
showed a much higher application potential as prospective
biomarkers of NSCLC. In the meta-analysis conducted by
He et al. [87], a single miRNA biomarker had a sensitivity
of 78.3% in detection of early-stage NSCLC, whereas a
miRNA panel had a sensitivity of 83%. Similar results were
reported by Wang et al. [88], who obtained a 77% sensitivity
and 71% specificity for a single miRNA, and 83% sensitivity
and 82% specificity for multiple miRNAs. It is essential to
comment, however, that the approximately 80% sensitivity
reported in those studies is of limited diagnostic use without
further stratification of the risk groups.
Importantly, several trials have shown promise for using
multiple miRNA signatures as biomarkers for screening or
evaluation of suspected cancer in high-risk groups. In the
MILD screening trial, investigators evaluated the diagnostic
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performance of plasma microRNAs as complementary bio-
markers for LDCT screening in a cohort of current or former
smokers, older than 50 years [6]. They retrospectively evalu-
ated plasma miRNA signatures in samples from 939 partici-
pants, including 69 patients with lung cancer and 870 disease-
free individuals. The diagnostic performance of miRNAs for
lung cancer detection was 87% for sensitivity and 81% for
specificity; a negative predictive value (NPV) of 99% and
the combination of both miRNA and LDCT resulted in a five-
fold reduction of the LDCT false positive rate. Similarly, an-
other group of investigators used a 13 miRNA signature on
1115 participants (heavy smokers, older than 50 years) in the
COSMOS lung cancer screening trial and reported sensitivity
and specificity of 79.2% and 75.9%, respectively, with an
NPVof 99% [88]. A negative result was found in 810 out of
the 1067 (76%) individuals without lung cancer and in 10 of
the 48 (21%) individuals with lung cancer, and the authors
suggested that the miRNA test could be used as a first-line
screening tool in high-risk individuals.
However, the usefulness of miRNAs extends beyond the
early detection of NSCLC [89, 90]. miRNA panels offer the
possibility to differentiate NSCLC from benign lesions and to
determine the histological tumour type from a tissue sample
[87, 91], with sensitivities and specificities within the range of
60–100%. In their analysis, Boeri et al. [89] suggested that
specific miRNAs detectable in plasma samples collected from
healthy smokers with an average exposure of 40 pack-years
allowed the identification of those with NSCLC 1–2 years
before the first symptoms of lung cancer became evident
and allowed determination of their prognoses. Cazzoli et al.
[92] screened 742 miRNAs isolated from circulating
exosomes and identified four miRNAs (miR-378a, miR-379,
miR-139-5p and miR-200b-5p) as screening markers to seg-
regate lung adenocarcinoma and granuloma patients, from
healthy former smokers (AUC= 0.908; P < 0.001). Then they
identified six miRNAs (miR-151a-5p, miR-30a-3p, miR-
200b-5p, miR-629, miR-100 andmiR-154-3p) that segregated
lung adenocarcinoma patients and lung granuloma patients
(AUC= 0.760; P < 0.001). Early detection of lung cancer
using specific miRNAs, which in most cases is not pos-
sible with conventional imaging methods, offers pros-
pects that more sensitive diagnostic algorithms will be
developed. In contrast to studies investigating the use-
fulness of miRNAs as diagnostic and prognostic
markers, relatively little attention has been devoted to
verification of the predictive significance of miRNAs
in the treatment of NSCLC.
3.1 miRNA as a Noninvasive Predictor for Recurrence
and Survival After Surgical Treatment of Lung Cancer
Surgery remains the only potentially curative modality for
early-stage NSCLC patients. However, 30% to 55% of
patients with NSCLC develop recurrence and die of their dis-
ease despite curative resection. While recurrence most com-
monly occurs at distant sites [93], there has also been a report
concerning the underestimation of the frequency of local re-
currence [94]. There is an urgent need for the identification of
new predictive factors to improve long-term survival rates.
Intensive follow-up is also important to reduce lung cancer
mortality by the early detection of recurrences after surgery.
The clinical value of miRNA expression in resected NSCLC
to identify patients at high risk of relapse after surgery is cur-
rently being evaluated.
Leidinger et al. [95] followed the plasma levels of miRNAs
in five lung cancer patients starting prior to surgery and ending
18months after surgery, with blood taken at 3-month intervals
(eight different time points). In terms of the quantitative
changes in miRNA abundance in plasma samples, the fewest
miRNAs were detected 6 months after cancer resection, while
the most miRNAs at about 2 weeks after cancer resection that
probably reflected the extensive tissue trauma and healing
processes. A correlation analysis of all miRNAs revealed 17
miRNAs that showed a general decrease over time while 16
miRNAs showed an increase. Importantly, this data clearly
contradicts the idea of a general decrease of circulating
miRNAs after tumour surgery (a decrease was found for spe-
cific miRNAs only) indicating that fluctuating patterns of
miRNA levels during the follow-up are patient-specific.
miR-486-5p was detected in all five samples before surgery
and showed a rather strong increase in expression over time.
In a further study, the same group observed a significantly
increased number of miRNAs detectable in the plasma of
eight NSCLC patients developing metastases with respect to
18 subjects without progressive disease (on average, 316 ver-
sus 286 miRNAs, respectively; P = 0.0096) [96].
It is worth noting that downregulated plasma miR-486 levels
after surgery have recently been associated with prolonged
recurrence-free survival of NSCLC patients [97]. Consistently,
in the study of Hu et al. [98], the serum levels of the oncogenic
miR-486 and miR-30d were significantly increased while those
of the oncosuppressor miRNAs (miR-499 and miR-1) were sig-
nificantly decreased in the group of NSCLC patients with a
shorter overall survival (23.97 months), as compared with pa-
tients with longer survival (47.17 months). Also, Le et al. [99]
reported that high expressions of miR-21 and miR-30d in preop-
erative sera were independently correlated with shorter overall
survival in a cohort of 82 lung cancer patients (log-rank test for
miR-21 and miR-30d: P = 0.0498 and P = 0.0019, respectively).
The findings mentioned above imply that changes of selected
miRNA levels in plasma or serum in response to surgery can
be a promising blood-based marker for predicting local recur-
rence of tumours and survival in NSCLC patients after surgery.
Still, this data needs to be verified in an independent study on a
larger cohort of lung cancer patients, and using uniform
methodology.
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3.2 miRNAs as Predictive Biomarkers in NSCLC
Radiotherapy
Radiotherapy, through ionising radiation, aims to destroy tu-
mours by causing the production of free radicals in the neo-
plastic cell (particularly, but not only, on the DNA) [100]. The
natural biological heterogeneity of NSCLC is one of the major
factors contributing to the diversity of responses to radiother-
apy observed in patients with this particular tumour type.
Resistance of lung cancer to ionising radiation may result
from chronic tumour hypoxia, disturbed DNA damage re-
sponse (DDR) pathways, deregulation of pathways responsi-
ble for cell survival and cell death via constitutive activation of
growth factor receptors (e.g. EGFR), mutations in oncogenes
(e.g. KRAS) or tumour suppressors (e.g. PTEN), and the pres-
ence of radiation-resistant cancer stem cells with a high regen-
erative and proliferative potential in hypoxic areas of the tu-
mour [101]. If it becomes possible to determine the degree of
tumour sensitivity/resistance to radiotherapy, clinicians could
use this treatment modality with greater accuracy by
optimising the selection of radiation dose and irradiation site,
and by limiting radiation toxicity. Some studies have focused
on the regulation of radiosensitivity by miRNAs and its clin-
ical implications for radiotherapy, most of them performing
cell culture experiments only (Table 2). In summary, many
in vitro studies have shown that sensitivity or resistance to
ionising radiations can be regulated by an increase or reduc-
tion of specific miRNA levels and the result depends on the
cell type, specific miRNA up- or downregulated, and pathway
triggered or silenced by downstream effects. Targeting specif-
ic miRNAs could enhance radiosensitivity or limit
radioresistance, thus producing more relevant clinical effects
in response of the cancer patient to radiotherapy.
Only few studies used patient specimen data, defining ra-
diosensitivity and radioresistance miRNA signatures. Wang
et al. [110] found 12 differently expressed miRNAs in
radiotherapy-sensitive and radiotherapy-resistant NSCLC
samples (n = 30).When comparing with resistant patients, five
miRNAs (miR-126, miR-let-7a, miR-495, miR-451 and miR-
128b) were significantly upregulated and seven miRNAs
(miR-130a, miR-106b, miR-19b, miR-22, miR-15b, miR-
17-5p and miR-21) were downregulated in the radiotherapy-
sensitive group. Overexpression of miR-126 increased the ra-
diosensitivity of lung cancer cells through the PI3K-Akt
pathway.
Bi et al. [111] profiled circulating miRNAs in serum sam-
ples from 100 unresectable NSCLC patients treated with de-
finitive radiotherapy. The serum miR-885/miR-7 signature
was identified as a significant predictor for overall survival
in the training set (n = 50), which was validated by the valida-
tion set (n = 50, P = 0.02). This signature remained significant
(P = 0.04) after adjustment for total tumour volume and
Karnofsky performance status, the only two significant clini-
cal factors in a univariate analysis. In the group treated with
high-dose radiation (>70 Gy, n = 45), low-risk patients had a
significantly longer overall survival than high-risk patients
(70.7 vs. 18.8 months, P = 0.007) while in the low-dose radi-
ation group (≤70 Gy, n = 55), no significant association was
observed.
Chen et al. [112] identified 14 miRNAs associated with
radioresistant genes (miR-153-3p, miR-1-3p, miR-613, miR-
372-3p, miR-302e, miR-495-3p, miR-206, miR-520a-3p,
miR-328-3p, miR-520b, miR-1297, miR-520d-3p, miR-
193a-3p and miR-520e) and five miRNAs associated with
radiosensitive genes (let-7c-5p, miR-98-5p, miR-203a-3p,
miR-137 and miR-34c-5p) on the basis of miRNA profiles
screened from NSCLC cell lines with different radiosensitiv-
ities. Next they correlated the expression of candidate
miRNAs in the plasma of 54 NSCLC patients with their ra-
diotherapy response to identify circulating radiosensitivity
biomarkers in NSCLC. Four miRNAs (miR-98-5p, miR-
302e, miR-495-3p and miR-613) demonstrated a higher ex-
pression in responders (complete response + partial response,
15 cases) than in non-responders (stable disease + progressive
disease, 39 cases). Based on each cut-point, objective re-
sponse rate was higher in the miR-high group than in the
miR-low group. NomiRNA showed correlation with survival.
3.3 miRNAs and Resistance to Lung Cancer
Chemotherapies
The available studies suggest that miRNAs not only regulate
the response to chemotherapy but are also regulated by che-
motherapeutic agents. Thus, the use of specific agents directly
affecting the activities of specific miRNAs, which may lead to
the development of a new cancer treatment strategy, is as
important as identifying miRNAs that are useful in monitoring
the course of traditional chemotherapy. The most recent re-
ports suggest that a patient’s response to a chemotherapeutic
agent is accompanied by changes in the expression of specific
miRNAs, which clearly implies that these molecules can be
used as predictive biomarkers (Fig. 3) [113].
3.3.1 Platinum
Cui et al. [114] proposed miR-125b as a potential negative
predictive biomarker of the response to cisplatin treatment.
In a study investigating 260 patients with advanced NSCLC
(stages IIIA–IV), high serum expression of this miRNA was
correlated with a poorer treatment response. Furthermore,
high serum expression of miR-125b in patients receiving
cisplatin-based chemotherapy was associated with shorter sur-
vival. Many currently ongoing studies are based on the anal-
ysis of miRNAs in NSCLC cell cultures as in vitro models of
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the mechanisms of sensitivity and resistance of this tumour to
chemotherapeutic agents. Gao et al. [115] demonstrated that
transfection of A549 lung adenocarcinoma cells (resistant to
platinum-based chemotherapy) with synthetic antisense oligo-
nucleotides targeting miR-21 (anti-miR-21) resulted in a con-
siderable increase in the expression of the PTEN tumour sup-
pressor and a decrease in the expression of the anti-apoptotic
BCL2. miR-21 expression was also associated with the shorter
disease-free survival in platinum-based chemotherapy-resis-
tant patients. In another study, overexpression of miR-513a-
3p, induced in the A549 cell line by transfection with miRNA
mimics (synthetic oligonucleotide sequences that mimic the
body’s endogenous miRNA), promoted cisplatin-dependent
apoptosis of cells previously resistant to this chemotherapeutic
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Let-7g Anti-miR Downregulation A549 Radiosensitivity ↑
miR-7 Mimic Overexpression A549 Radiosensitivity ↑ – – EGFR and Akt
signalling
[103]
miR-34a Mimic Overexpression A549
H1299






miR-214 Anti-miR Downregulation U-1810 Radiosensitivity ↑ – – p27Kip1 dependent
senescence
[106]
Mimic Overexpression H23 Radioresistance ↑ – – p38MAPK pathway
miR-328-3p Mimic Overexpression A549, H23,
H460,
H1299






miR-451 Mimic Overexpression A549 Radiosensitivity ↑ – – Upregulation of PTEN [108]
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Fig. 3 miRNAs involved in
mechanisms of resistance to
various chemotherapeutic
strategies and TRAIL-based ther-
apy in NSCLC. Some miRNAs
act as oncogenes by downregu-
lating the genes involved in pro-
apoptotic pathways thus promot-
ing the survival of tumour cells.
Therapeutic silencing of those
miRNAs could potentially sensi-
tize tumour cells to the drugs.
Other miRNas function as tumour
suppressors that target the genes
promoting tumour cell survival.
Induced overexpression of these
miRNAs might increase the ther-
apeutic effect that depends on the
apoptosis of the tumour cells
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agent [116]. Interestingly, miR-513a-3p negatively regulated
the production of glutathione S-transferase by cancer cells,
which was linked to resistance to cisplatin [117, 118]. These
results demonstrate that miRNAs may not only be used as
markers of the response to cisplatin but also as potential treat-
ment tools that stimulate the sensitivity of lung cancer cells to
this chemotherapeutic agent.
3.3.2 Taxanes
Rui et al. [119] found a significant association between the
level of miR-200b expression in SPC-A1 lung adenocarcino-
ma cells and the resistance of these cells to docetaxel. As a
result of induced overexpression of miR-200b in tumour cells,
decreased resistance to this chemotherapeutic agent was ob-
served, which was explained by suppression of proliferation
and augmentation of the apoptotic pathway [120]. In another
in vitro study, miR-200b was suggested as a chemosensitivity
restorer to docetaxel therapy in lung adenocarcinoma cells by
targeting E2F3. This transcription factor is critical for the
maintenance of regular cell cycle progression [120]. Also
miR-100 has been shown to have an impact on increasing
the chemosensitivity of SPC-A1 cancer cells to docetaxel by
reducing the expression of PLK1 [121]. The inverse correla-
tion betweenmiR-100 and PLK1 expressionwas also detected
in nude mice SPC-A1/DTX tumour xenografts and clinical
lung adenocarcinoma tissues and was proved to be related to
the in vivo response to docetaxel. In other study conducted by
Cui et al. [122], the restoration of let-7c had an ability to
reverse the chemoresistance of docetaxel-resistant lung ade-
nocarcinoma cells owing to direct targeting of BCL-xL and
inactivation of Akt phosphorylation both in vitro and in vivo.
A study investigating the expression of EZH2, a gene
overexpressed in NSCLC, showed that miR-101 was capable
of inhibiting the growth of tumour cells by inducing the apo-
ptotic pathway associated with the therapeutic effects of pac-
litaxel [123]. To determine the effects of miR-101 in lung
cancer cells, the cells were transfected with miRNA mimics.
This led to a decrease in the proliferation and invasiveness of
the tumour cells by sensitizing the NSCLC cell to paclitaxel,
which was partly due to decreased expression of EZH2.
Results of in vitro studies on the established lung cancer cell
line A549 demonstrate that an important role in the mecha-
nism of resistance to paclitaxel is played by miR-16 and miR-
17, whose expression profiles were significantly correlated
with the resistance of tumour cells to this chemotherapeutic
agent [124, 125]. In another in vitro study, resistance of the
same cell line to paclitaxel was significantly associated with
miR-135a expression [126]. In both in vitro and in vivo
models, researchers observed that inhibition of miR-135a ex-
pression led to re-sensitization of previously resistant NSCLC
cells to paclitaxel and caused the cells to undergo apoptosis.
Expression of miR-135a has also been linked to the activity of
the APC gene, which is involved in cancer development. Shen
et al. [127] showed that miR-137 also has a potential role in
drug resistance of lung cancer cells. After the repression of
miR-137 in A549 cells, cell growth, migration and cell sur-
vival were increased. Importantly, induced overexpression of
miR-137 underlined a tumour suppressive role of this miRNA
in chemosensitivity by the inhibition of cell growth and an-
giogenesis in vivo. In a xenograft mouse model, miR-186 also
showed tumour growth inhibitory functions [128]. This
miRNA directly targeted MAPT and the chemosensitizing
function of miR-186 was partially caused by the induction
of the p53-mediated apoptotic pathway.
3.4 miRNAs as Key Modulators of Tumour Immune
Response in Lung Cancer Patients
Advances in our understanding of the mechanisms responsi-
ble for the regulation of tumour-directed immune response
have led to the development of immune checkpoint inhibitors,
currently an established therapeutic option for patients with
advanced NSCLC. These agents target molecular pathways
orchestrated by the programmed cell death protein-1 (PD-1)/
programmed cell death ligand-1 (PD-L1) interaction. PD-L1
expression is directly involved in evasion of the immune re-
sponse by cancer cells [10]. Its binding to the PD-1 receptor
on T cells promotes a dual inhibition mechanism: firstly, by
inducing apoptosis in antigen-specific Tcells and secondly, by
simultaneously reducing regulatory T cell (Treg) apoptosis.
Thus, via this PD-1/PD-L1 interaction, the tumour is able to
induce the anergy of T cells and avoid the recognition by the
immune system [129]. Clinical trials have demonstrated sig-
nificant clinical effects of PD-1 or PD-L1 blockade in ad-
vanced NSCLC patients [130]. Currently, there are three
checkpoint inhibitors of the PD-1/PD-L1 pathway approved
by the Food and Drug Administration (FDA) to treat advanced
disease: pembrolizumab (approved for PD-L1-positive
NSCLC), nivolumab and atezolizumab (regardless of PD-L1
expression status). Inhibitors targeting other immune check-
points, such as anti-CTLA-4 antibodies, have not resulted in
benefits from single-agent response.
Recently, a molecular link between the evasion of the im-
mune response by lung cancer cells and the miRNA function
has been identified. Chen et al. [131] demonstrated that miR-
200 suppressed the epithelial to mesenchymal transition
(EMT) process by targeting PD-L1 and thus delaying cancer
progression in a mouse model. As shown before, miR-200
expression is downregulated in highly metastatic cancer cells
[132, 133]. By inducing its expression, a reversed EMT phe-
notype was induced with abolished invasion and metastasis
formation. miR-200 family members (arranged in two geno-
mic cluster: miR-200a/200b/429 and miR-200c/141) directly
target EMT-inducing transcription factors such as zinc finger
E-box-binding homeobox 1 (ZEB1) [131]. ZEB1 regulates the
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miR-200 family expression by repressing the transcription of
both miR-200 loci. In cancer cells, the miR-200/ZEB1 axis
controls the expression of multiple genes involved in migra-
tion, invasion and metastatic growth at distant sites. Thus,
miR-200 and ZEB1 form a double-negative feedback loop
and function as a key regulatory axis of the EMT program.
ZEB1 as the transcriptional repressor of miR-200 plays a crit-
ical role in the upregulation of PD-L1 expression on tumour
cells followed by CD8+ T cell immunosuppression and
metastasis.
It has also been observed that miR-200 expression nega-
tively correlates with PD-L1 expression, particularly in tu-
mours with a mesenchymal phenotype. This finding impli-
cates the potential usefulness of miR-200 expression as a pre-
dictive biomarker for checkpoint inhibitor therapy in NSCLC.
On the basis of evidence presented above, lung cancer patients
presenting an adenocarcinoma subtype with upregulated PD-
L1, mesenchymal expression pattern and low miR-200 ex-
pression would particularly benefit from the treatment with
PD-1/PD-L1 inhibitors.
PD-L1 can also be regulated by p53 via the miR-34 family,
which directly binds to the 3′UTR of the PD-L1 transcript
[134]. NSCLC patients with high miR-34a/p53 and low PD-
L1 levels are characterized by higher survival rates than those
with low miR-34a/p53 and high PD-L1 levels. These findings
have potential clinical application and further studies are need-
ed to confirm the usage of miR-34a/p53 expression as a pre-
dictive biomarker for immunotherapy. Novel mechanisms un-
derlying the regulation of tumour immune evasion by specific
miRNAs are currently investigated.
3.5 miRNAs as Modulators of TRAIL-Based Therapy
Tumour necrosis factor (TNF)-related apoptosis inducing li-
gand (TRAIL) is a cytokine and a member of the TNF family
that is being tested in clinical trials as a powerful anticancer
agent. Although TRAIL had shown clinical efficacy in a sub-
set of NSCLC patients, acquired resistance to this anticancer
agent undermines its therapeutic value. The mechanism of this
resistance is still not fully understood.
In 2008, Garofalo et al. [85] reported that NSCLC cells
overexpressing miR-221/222 were TRAIL-resistant and
showed an increase in migration and invasion capabilities.
Later on, the same group [135] demonstrated that miR-34a
and miR-34c, which are downregulated in NSCLC cell lines,
could play a significant role in lung carcinogenesis by modu-
lating the expression of PDGFR-α/β and thereby regulating
TRAIL-induced cell death sensitivity. Another miRNA that
can be involved in TRAIL resistance is miR-24 [136]. This
miRNA directly downregulates the expression of XIAP and
induces sensitivity to TRAIL-based therapy in TRAIL-
resistant lung cancer cell line. Joshi et al. [137] showed that
enforced expression of miR-148a sensitized cells to TRAIL
and reduced lung carcinogenesis both in vitro and in vivo
through the downregulation of matrix metalloproteinase 15
(MMP15) and Rho-associated kinase 1 (ROCK1). Although
miRNAsmay lead to re-sensitization of cancer cells to TRAIL
therapy, there are also miRNAs which play the opposite role
and promote TRAIL resistance. Expression of miR-21, miR-
30c and miR-100 in NSCLC has been related to acquired
TRAIL resistance [138]. Accordingly, continuous exposure
to TRAIL caused acquired resistance to this agent and activat-
ed miR-21, miR-30c and miR-100 transcripts.
3.6 miRNAs as Biomarkers for Targeted Therapies
in NSCLC
NSCLC is a challenging diagnostic target due to the consid-
erable diversity of neoplastic clones within the tumour and the
difficult access to good-quality and informative diagnostic
material [139]. As the disease progresses, the profile of mo-
lecular markers changes as a result of the genetic alterations
within the tumour [140]. miRNAs are associated with tumour
progression, suggesting their potential applications for
targeted treatment monitoring.
Targeted therapy with tyrosine kinase inhibitors (TKIs) is
currently the most common form of personalised treatment of
NSCLC. Somatic mutations in exons 18 to 21 of the EGFR
gene are the most important molecular predictive marker
whose clinical value in the diagnosis of NSCLC has been
confirmed [141]. EGFR mutations occur in about 30–50%
of Asian and approximately 10–20% of Caucasian NSCLC
patients. In contrast to standard chemotherapy, TKIs selective-
ly inhibit tumour cell growth by affecting the intracellular
domain of EGFR [142]. Targeted therapy using TKIs, which
either bind to EGFR reversibly (erlotinib, gefitinib) or irre-
versibly (afatinib, osimertinib), is the clinical standard in the
personalised treatment of NSCLC for eligible patients. The
greatest limitation of the efficacy of reversible EGFR TKIs
is the resistance to these agents that is acquired by most pa-
tients during treatment, with a median time to progression of
9 months [143].
The aberrant expression of specific miRNAs or miRNA
families has serious consequences resulting in abnormal reg-
ulation of key components of signalling pathways in tumour
cells (Fig. 4). The dual activity of miRNAs (oncogenic or
suppressor) in carcinogenesis seems to be an important factor
affecting the efficacy of targeted therapies, including EGFR
TKIs in lung cancer [144]. Abnormal regulation of gene ex-
pression bymiRNAs triggers alternative (collateral) signalling
pathways or activates downstream signalling mediators,
bypassing the pathway blocked by EGFR TKIs. As a result
of the feedback between miRNA levels and the activity of the
genes targeted by the given miRNA, including oncogenes and
tumour suppressors, miRNA expression may change dynam-
ically, indicating the current status of the cell’s genetic activity.
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Identification of miRNA profiles involved in the mechanisms
of the cellular response to EGFRTKIs may open a new direc-
tion of research to develop a more effective personalised ther-
apy for patients with NSCLC [145]. It could also significantly
increase the efficacy of disease and treatment monitoring.
Non-invasive approaches, usually based on plasma or se-
rum samples, showed great potential for monitoring EGFR-
TKI treatment in recent years. Several circulating miRNA
signatures are associated with response to EGFR-TKIs in
NSCLC. Zhang et al. [146] analysed the expression of 20
miRNAs in the plasma of 105 non-smoking female patients
with lung adenocarcinoma (stage I–IV). They found miR-122
to be differently expressed between wild and mutant EGFR
carriers (P = 0.018). After adjusting for stage, the associations
of miR-16, miR-20b, miR-195, miR-122 and miR-486-3p
with EGFR mutation status were evident in advanced stage
(P = 0.019, 0.047, 0.041, 0.033, or 0.017, respectively).
Plasma levels of miR-195 and miR-122 expression were also
associated with overall survival in the patients, especially in
those with advanced stage (HR = 0.23, 95% CI 0.07–0.84;
and HR = 0.22, 95% CI 0.06–0.77).
Shen et al. [147] reported that the expression levels of serum
miR-21 and miR-10b were much higher in 128 radically
resected NSCLC patients with EGFR mutation (n = 60) than
those without mutation (n = 68). In both univariate and multi-
variate analyses, gefitinib treatment was associated with a sig-
nificant improvement in overall survival in patients with re-
duced miR-21 expression. Thus, miR-21 expression emerged
as an independent predictor of the response to EGFR-TKI.
In another study, upregulation of five selected miRNAs
(miR-21, miR-122, miR-195, miR-125b, miR-25) correlated
significantly with EGFR mutation in both tumour tissues and
matched plasma of 150 NSCLC patients (all P < 0.001) [148].
The discriminatory power of predicting EGFRmutation using
plasma miRNAs was demonstrated by the AUC (area under
the curve) of 0.869 (P < 0.001, 95% CI 0.808–0.930).
Wang et al. [149] studied the role of miRNAs in primary
resistance to EGFR-TKIs in advanced NSCLC patients with
EGFR mutation. First, they found 153 miRNAs that were
differentially expressed between the sensitive and resistant
groups in a training cohort of 20 advanced NSCLC patients
with EGFR exon 19 deletions treated with first-line EGFR-
TKIs. Then, three miRNAs (miR-21, miR-27a and miR-218)
were verified to have significantly higher expression (P =
0.011, 0.011, 0.026, respectively) in the resistant group com-
pared to the sensitive group in a validation cohort (n = 34).
This is the first study that identified a potential association
between miR-21 and primary resistance to EGFR-TKIs in
EGFR-mutant patients.
Interestingly, another study showed that miR-21 is in-
volved in acquired resistance of EGFR-TKI in NSCLC
[150]. The serum miR-21 expression in 25 advanced
NSCLC patients treated with EGFR-TKI was significantly
higher at the time of acquiring resistance than at baseline
(P < 0.01). Moreover, the authors provided mechanistic evi-
dence based on animal models that miR-21 can mediate
EGFR-TKI resistance by downregulating PTEN and
PDCD4, and activating the PI3K/Akt pathway. PTEN
is a tumour suppressor protein which negatively regu-
lates the PI3K/Akt pathway by converting phos-
phatidylinositol 3,4,5-triphosphate (PIP3) to phos-
phatidylinositol 4,5-bisphosphate (PIP2) [151]. Allelic
loss or mutation of PTEN is common in many human
malignancies and PTEN abnormality-associated Akt ac-
tivation (PI3K/Akt pathway) has been known to play an

























Fig. 4 miRNA regulation of the
key signalling pathways involved
in the efficacy of EGFR TKI
treatment in NSCLC
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About 20–44% of treated NSCLC patients acquire resis-
tance to EGFR-TKIs through phenotypic changes of the tu-
mour cells undergoing EMT, possibly as a result of altered
epigenetic regulation [152]. It has been shown that EMT-
related acquired resistance to EGFR-TKIs in NSCLC is driven
by increased ZEB1, which is negatively regulated by miR-
200c [153]. Interestingly, clinical results by Li et al. [154]
showed that wild-type EGFR patients with high miR-200c
expression (n = 26) could benefit more from EGFR-TKIs than
those with low miR-200c expression (n = 40), while no such
effect was observed in the mutant EGFR subgroup (n = 73).
Patients with high miR-200c expression had significantly bet-
ter clinical outcomes than those with low expression in terms
of progression-free survival (5.0 months [95% CI 1.41–8.59]
vs. 1.2 months [95% CI 0.89–1.51), P = 0.001), overall sur-
vival (9.6 months [95% CI 4.27–14.93] vs. 5.0 months [95%
CI 3.90–6.10], P = 0.037), and a numerically higher objective
response rate (11.5% vs. 2.5%, P = 0.292). This study implies
that miR-200c overexpression might be a potential predictive
biomarker for the outcome of EGFR-TKIs in advanced
NSCLC patients with wild-type EGFR.
The available literature pertaining to the role of miRNAs in
the sensitivity and resistance to molecularly targeted therapies
other than EGFR TKIs is very sparse. Currently, it is recom-
mended that newly diagnosed patients with advanced lung
adenocarcinoma are tested for EGFR mutations and ALK fu-
sions [155, 156]. Additionally many clinical laboratories are
now routinely testing for alterations in genes such as ROS1,
RET,MET, BRAF and HER2 which have shown initial prom-
ise in tailored cancer treatment.
Chromosomal rearrangements of ALK are present in 3–7%
of NSCLC. The resulting ALK fusions, such as EML4-ALK,
function as potent oncogenic drivers and lead to a state of
oncogene addiction [156]. In the clinic, this phenomenon un-
derlies the marked responsiveness of ALK-positive tumours
to crizotinib, a multitargeted tyrosine kinase inhibitor (TKI) of
ALK, ROS1 and c-MET [157]. Despite the impressive efficacy
of crizotinib in the treatment of ALK-positive lung cancer,
acquired resistance eventually develops in the majority of pa-
tients [158]. In a recent study, Gao et al. [159] reversed EMT
in a crizotinib-resistant NSCLC cell line through overexpres-
sion of miR‑200c targeting ZEB1, thus providing further evi-
dence on the role of miRNAs in mediating sensitivity of tu-
mour cells to TKIs.
The MET/hepatocyte growth factor (HGF) pathway has
been identified as a potential therapeutic target in multiple
solid tumours, including NSCLC [156]. In NSCLC, the most
common mechanism for aberrant MET signalling is overex-
pression of HGF and HGFR. Importantly,MET amplification
has been identified as a mechanism for acquired resistance to
EGFR tyrosine kinase inhibition in a subset (5–20%) of pa-
tients with activating EGFR mutations through ERBB3-
dependent activation of the PI3K pathway. There are a number
of MET tyrosine kinase inhibitors currently undergoing test-
ing in early phase clinical trials [160]. Although crizotinib is
FDA-approved for ALK-translocated NSCLC, it also has
in vitro activity against MET.
The miR-34 family consists of three members: miR-34a,
miR-34b and miR-34c; all of them negatively regulate the
MET gene [161]. All members of the miR-34 family, targeting
more than 77 target mRNAs, were shown to suppress tumour
growth and metastasis by inhibiting the processes that stimu-
late cancer development, including cell cycle progression,
EMT, metastasis, stemness and by promoting the processes
that inhibit carcinogenesis, such as apoptosis [162]. miR-
34b/c (and miR-199) contributes to control MET activity by
binding to the 3′UTR ofMET [163]. The transfection of cells
with miR-34b/c precursors showed a significant reduction of
MET protein even in cells displaying overexpression and
MET gene amplification; furthermore the transfected cells
were unable to migrate and to scatter (to break intercellular
junctions) in response to HGF. Conversely, the inhibition of
endogenous miR-34b/c by use of antagomiRs resulted in in-
creased expression of MET.
The members of the miR-221/222 cluster are among the
oncogenic miRNAs that target MET [161]. Garofalo et al.
[164] studied miRNAs implicated in EGFR resistance and
identified eight miRNAs that are regulated by both EGFR
and MET (miRNAs: 221/222, 30b/c, 21, 29a/c, 100). Then
they demonstrated that gefitinib treatment triggers pro-
grammed cell death through the downregulation of miR-
30b/c and miR-221/222 in sensitive NSCLC cells.MET over-
expression is able to induce resistance to gefitinib through the
upregulation of miR-30b/c and miR-221/222 making the
EGFR inhibition alone ineffective. They also showed that this
resistance could be overcome using MET inhibitors or anti-
miRNA 221/222 and anti-30c which strongly increase gefitin-
ib sensitivity in xenograft mouse models in vivo.
4 miRNAs as Therapeutic Agents in NSCLC
Treatment
The pathogenesis of lung cancer is characterised by extensive
epigenetic and genetic changes that include mutations, rear-
rangements, changes in gene expression, and chromosomal
amplifications and deletions. Therefore, an ideal targeted ther-
apy should focus on many key coding and/or regulatory se-
quences involved in the process of carcinogenesis. A signifi-
cant advantage of using miRNAs as potential targets and/or
treatment agents is their ability to regulate the expression of a
number of genes and non-coding sequences that are associated
with a single pathway or are involved in the regulation of
parallel signalling pathways that control tumour development
[165]. Compared with treatment based on small interfering
RNAs (siRNAs), each of which can only silence one gene,
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the use of miRNAs as treatment agents seems much more
beneficial. For example, multiple genes in the EGFR signal-
ling pathway, including MAPK, STAT3 and AKT2, are all po-
tential targets of miR-124 [166].
Therapies based on miRNAs are being developed with two
objectives. The first involves inhibition of specific miRNA
molecules if their expression levels are pathologically elevat-
ed. The second involves supplementation of those miRNAs
whose cellular expression is insufficient or lacking. miRNA
activity may be regulated by inhibiting or supplementing a
specific miRNA sequence or by modulating the expression
of the miRNA coding sequence. In the latter method, the treat-
ment agents are mainly siRNAs and genetically engineered
expression vectors that encode small hairpin RNAs. The po-
tential application of each of the proposed strategies depends
on the tumour type, tumour stage and, most likely, many other
previously unknown clinicopathological factors [167].
Oligonucleotides that act as miRNA antagonists (anti-
miRs) are being designed to disrupt the biogenesis of
miRNAs, resulting in increased expression of suppressor
genes. miRNA mimics, which are also referred to as replace-
ment therapy for miRNAs, are characterised by another mech-
anism of action. The decrease in the activity of suppressor
miRNAs during cancer progression may be compensated for
by miRNA mimics that have the same actions as those of the
native molecules.
4.1 Preclinical Studies
It is estimated that only about 200 out of approximately 2500
mature human miRNAs registered in miRBase have suffi-
ciently high expression to be feasible targets for mechanistic
studies or therapeutic purposes [168]. Recent studies have
focused on aberrant expression of the let-7 and miR-34 fam-
ilies in lung tumour tissues when compared to the normal lung
tissue, which can indicate the involvement of those miRNAs
in lung carcinogenesis [169].
Several studies have shown that downregulated expression
of let-7, one of the earliest discovered miRNAs, was associat-
ed with poor prognosis in lung cancer patients [170–173].
This association was later proposed to be due to the
let‑7‑mediated inhibition of RAS, which is a critical oncogene
that is involved in lung cancer development [174]. Induced
overexpression of let-7 in lung adenocarcinoma A549 cells
with mutated KRAS showed cancer cell growth inhibition
and reduction in cell cycle progression by modulation of
CDC25A, CDK6 and cyclin D2 [175]. Let-7 suppresses tu-
mour growth in xenograft models of human lung cancer
[176, 177]. Mirna Therapeutics is currently developing let-7
as a potential miRNA replacement treatment for cancer [168].
miR-34 is another master tumour suppressor miRNA, the
downregulation of which is largely investigated in lung cancer
[178, 179]. miR-34 family members (a, b and c) are
responsible for cell cycle control, apoptosis and cell senes-
cence via the repression of several targets involved in carci-
nogenesis like BCL2 , MYC and MET genes [180].
Corresponding to the studies conducted by Garofalo et al.
[135], an important therapeutic application of miR-34 in lung
cancer therapy was further supported by studies on the effects
of miR-34 replacement on carcinogenesis in a mouse model
[181].
Wiggins et al. [182] demonstrated that the transfection of
tumour cells with synthetic miR-34a resulted in tumour
growth suppression in a mouse model. The negative influence
of this miRNA on the expression of genes determining tumour
cell survival (c-MET and BCL2) was also confirmed.
Importantly, accumulation of this miRNA in tumour tissues
was observed along with low nephro-, cardio- and hepatotox-
icity. Similarly, Trang et al. [183] reported a significant anti-
neoplastic effect (tumour mass reduction by 60%) by two
miRNA mimics, miR-34a and let-7, administered intrave-
nously as a complex with a neutral lipid emulsion, which
was preferentially taken up by lung tissue.
The therapeutic approach presented in another preclinical
work on miR-34 showed that this miRNA directly represses
the checkpoint molecule PD-L1 (programmed death ligand 1)
in a mouse model of non-squamous lung cancer [134].
Therapeutic delivery of MRX34 (miR-34 mimic) promoted
the TILs (tumour-infiltrating lymphocytes, CD8+) and re-
duced CD8 + PD1+ immune cells. This novel mechanism, in
which a tumour can evade the immune system, is regulated by
the p53/miR-34/PD-L1 axis and may be crucial for develop-
ing a new therapeut ic approach for lung cancer
immunotherapy.
miR-21 is an oncogenic miRNA and overexpressed in var-
ious types of human tumours including lung cancer [47].
Aberrant expression of miR-21 is considered to contribute to
the malignant phenotype, affect proliferation, apoptosis and
metastasis [184]. Mechanistically, overexpression of miR‑21
leads to the suppression of several key tumour suppressor
genes, such as PTEN, TPM1 and PDCD4 [168]. Thus,
miR‑21 was identified as one of the oncomiRs whose inhibi-
tion may have therapeutic benefits.
Seike et al. [185] reported that miRNA microarray data
showed higher levels of miR-21 in EGFR-mutant cases, and
in vitro analyses using NSCLC cell lines showed that activat-
ed EGFR signalling upregulated miR-21 expression. A statis-
tically significant positive correlation was observed between
miR-21 expression levels and p-EGFR levels in NSCLC cell
lines. Furthermore, treatment with the EGFR-TKI inhibited
miR-21 expression in two NSCLC cell lines with elevated p-
EGFR, providing a mechanistic link between an activated
EGFR signalling pathway and the aberrant upregulation of
miR-21.
Recently, Microlin Bio, Inc. announced positive results
from a preclinical lung cancer study using its lead anti-
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miRNA candidate in a murine lung cancer model [186]. Anti-
miR-21 (AM-21) was delivered using the company’s novel
QTsome® (QT) delivery platform, which is composed of a
combination of two cationic lipids with tertiary and quaternary
amine head groups, respectively. The company claimed that
animals in the 1 mg/kg IVQT/AM-21 treated group displayed
significant tumour regression or no tumour growth while un-
treated animals exhibited rapid tumour growth. Median sur-
vival was prolonged following treatment with QT/AM-21
from 21 days in the untreated group to 33 days in the 1 mg/
kg QT/AM-21 treatment group. Moreover, there were no ob-
vious signs of treatment-based toxicity. A summary of preclin-
ical studies for miRNA-based treatment is given in Table 3.
4.2 Clinical Studies
On the basis of the promising results of preclinical studies, the
miR-34 mimic was the first therapeutic miRNA agent to enter
clinical trials in phase I testing in patients with primary liver
cancer or metastatic cancer that has spread to the liver [179].
The leading therapeutic, MRX34, was a lipid-formulated
miR-34 mimic under development by Mirna Therapeutics
[191]. A study enrolled patients with unresectable primary
liver cancer or advanced metastatic cancer (e.g. NSCLC,
SCLC) with or without liver involvement or haematologic
malignancies. MRX34 was given as intravenous liposomal
injection. In September 2016, the clinical trial was terminated
because of multiple immune-related severe adverse events
(SAEs) observed in patients dosed with MRX34 over the
course of the trial [192]. To date, there are no other registered
clinical trials investigating the therapeutic use of miRNAs in
lung cancer.
4.3 Problems to Overcome
Therapies based on miRNAs have encountered a number of
obstacles. First, the multitargeted action of miRNAs, which
might potentate the efficacy of miRNA-based drugs, also
carries the risk of off-target effects resulting in frequently oc-
curring and severe adverse events in other organs [193].
Additionally, while miRNA mimicry increases the levels of
a miRNA that is lost during disease progression, systemic
delivery of such miRNA mimics can also result in uptake by
non-target tissues that normally do not express the miRNA of
interest, resulting in potential off-target effects [194]. Thus,
the development of an effective and safe system to deliver
miRNAs into tumour cells or their environment is going to
be important to prevent unwanted side effects of this therapeu-
tic approach.
One of the methods of introducing exogenous miRNA
molecules into tumour tissues involves transfection using a
viral vector. Transfection of synthetic let-7 molecules into
murine tumour cells caused the tumour mass to decrease
[187]. Unfortunately, using modified viral vectors in therapy
is still considered controversial by the medical community
because of the risk of viral DNA integration into undesirable
locations in the host genome, with the resulting transformation
of healthy somatic and germ line cells in the body. Also, the




Therapeutic approach Vector Molecular mechanisms Therapeutic effect Ref.




Growth inhibition of lung
cancer cell xenografts in
immunodeficient mice
[176]
Mimic Lentivirus 75% reduction in tumour
burden
[187]
Mimic Neutral lipid emulsion Reduced orthotopic tumour
burden
[183]
miR-34a Mimic Neutral lipid emulsion Negative regulation of
CDK4, c-MET
60% reduction in orthotopic
tumour burden
[183]
Mimic Cationic lipid Xenograft growth inhibition [182]
let-7 and miR-34a
combined




leading to a survival advantage
[188]
miR-29b Mimic Cationic lipoplex Reduced expression of
CDK6, DNMT3, MCL1










Tumour regression or no tumour
growth, prolonged survival
[186]
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level of expression of the exogenous gene is usually too low to
mount a full treatment effect [195]. Another method of trans-
ferring specific miRNA into the lung tumour tissue is a cat-
ionic lipid-based miRNA delivery system, which had good
efficiency both in vitro and in vivo, as was reported by Wu
et al. [189, 196]. Most challenges to overcome in liposome-
based therapies are related to toxicity due to charged lipo-
somes, inability to escape the immune system, and low stabil-
ity [197, 198]. Recently, as an alternative to the liposomal or
nanoparticle-based methods of miRNA delivery, the EDV™
nanocells (EDVs) have been employed [199, 200]. This de-
livery system developed by EnGeneIC Ltd (Sydney,
Australia) comprises nonviable minicells 400 ± 20 nm in di-
ameter, produced by de-repressing polar sites of cell division
in bacteria [201]. Once loaded, EDVs are coated with a
bispecific antibody (BsAB), where one arm is available for
binding to a receptor expressed on the surface of cancer cells.
Following intravenous administration, EDVs tend to accumu-
late in the tumour vasculature then bind to overexpressed tar-
get receptors on tumour cells and are thought to become in-
volved in the endocytosis process. EDVs not only deliver
toxic payloads to tumours, they stimulate the adaptive im-
mune system to augment the antitumour response.
The low in vitro stability of RNA is another problem.
Unmodified RNA molecules are degraded by RNases and
are excreted in the urine [202]. When RNA molecules were
administered via the tail vein inmice, they were removed from
the bloodstream within less than 30 min [183]. Effective
in vivo silencing of specific miRNAs which expression in-
creased pathologically requires the use of anti-miRs
characterised by improved biological stability, highly specific
miRNA binding and optimal pharmacokinetic properties,
which are achieved by chemical modification of the RNA
molecule [194]. In the case of miRNA mimics, in vivo stabil-
ity is ensured by the double-stranded structure of these mole-
cules and by protection of the leading strand, which is identi-
cal to the mimicked miRNA, by the addition of fluorine to
cytosine and uracil nucleotides (2′-FC and 2’-FU, respective-
ly) [203]. This modification does not interfere with the recog-
nition of miRNA mimics by the native RISC complex of the
recipient cell.
5 Summary
Nearly two decades have elapsed since the discovery of
miRNAs, and many studies have since focused on the possi-
bility of using these small regulatory molecules as biomarkers
for various cancer types, including NSCLC. As a result of the
involvement of miRNAs in carcinogenesis during all stages,
these molecules could be used not only as specific biomarkers
of cancer (diagnostic biomarkers) but also as dynamic markers
of the tumour status before (prognostic biomarkers) and
during treatment (predictive biomarkers). Extracellular
miRNAs, which are secreted in a stable form by tumour cells
into the blood and other body fluids during the early stages of
lung cancer development, seem to be particularly useful in
clinical practice. Their principal advantage is the ease by
which their quantitative and qualitative changes can be mon-
itored in real time and at every stage of the disease, without
causing patients discomfort by invasive collection of speci-
mens for testing.
Tremendous technological progress has been made over
the past decade in the methodology of miRNA detection and
identification, particularly in high-throughput techniques,
such as NGS. This has marked a new era of translational
research enabling simultaneous objective analysis of multiple
miRNAs in the context of identifying epigenetic profiles in
lung cancer. Bioinformatics tools have played an equally im-
portant role, enabling the analysis of raw data, the classifica-
tion of miRNA families and the prediction of potential target
genes.
In light of the existing expectations regarding the effective
use of miRNAs in the diagnosis and treatment of lung cancer,
there is an urgent need to continue basic research investigating
the biogenesis and functions of miRNA, as well as translation-
al research to verify the possibilities of their practical applica-
tions as biomarkers in the clinic. Although these small, non-
coding RNA particles clearly possess many desirable proper-
ties to become Bideal^ biomarkers for lung cancer diagnosis
and treatment effectiveness monitoring, only few of all the
known miRNAs will actually pass strict validation processes
to reach clinical approval.
Also, the concept of using miRNAs in the personalised
therapy of lung cancer, which involves modulating the expres-
sion of specific miRNAs that regulate the activity of genes
involved in carcinogenesis, seems realistic providing that sev-
eral problems of key importance are solved. First, effective
delivery of miRNA modulators to the cell type or tissue of
interest should be developed. Next, better understanding the
side effects and potential off-target effects under physiologi-
cally normal and diseased conditions in vivo is essential in
order to bring miRNA therapeutics closer to the clinic.
Furthermore, extensive preclinical studies are required to de-
termine the optimal level of inhibition for a given miRNA
target. Finally, well-designed clinical trials need to be con-
ducted to test which patients are more likely to benefit from
miRNA-based therapy. As the number of studies evaluating
the applicability of miRNA for lung cancer diagnosis, prog-
nosis and treatment is increasing continuously, one can expect
the true potential of miRNAs as either biomarkers and/or ther-
apeutics to come to light shortly in coming years.
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